Astria Therapeutics to Showcase Navenibart Data for Hereditary Angioedema at International Workshop in Budapest

Astria Therapeutics, a biopharmaceutical company dedicated to developing groundbreaking therapies for allergic and immunologic conditions, has announced its participation in the 14th C1 Inhibitor Deficiency and Angioedema Workshop in Budapest, Hungary, on May 31, 2025. Dr. Marc A. Riedl, a leading expert and Professor of Medicine at the University of California, San Diego, will present critical data on the company's drug, navenibart, during this event. Dr. Riedl's presentation, titled "Navenibart for Hereditary Angioedema (HAE): Analysis of Safety, Pharmacokinetic, and Pharmacodynamic Data From Phase 1a and Phase 1b/2 ALPHA-STAR Trials," is scheduled for 2:45 PM CET at the Ensana Thermal Hotel Margitsziget. The workshop aims to gather experts from around the world to discuss advancements and challenges in treating C1 inhibitor deficiency and related angioedema disorders. Dr. Riedl’s data will provide valuable insights into the potential of navenibart as a new therapeutic option for HAE patients. Hereditary Angioedema (HAE) is a rare genetic disorder characterized by recurrent episodes of severe swelling, particularly affecting the face, throat, hands, feet, and genitals. These episodes can be painful, disfiguring, and, in some cases, life-threatening if they obstruct airways. Current treatments include preventive measures and on-demand medications, but there remains a significant unmet need for more effective and safer therapies. Navenibart, also known as STAR-0215, is a monoclonal antibody designed to inhibit plasma kallikrein, a key enzyme involved in the pathophysiology of HAE. In the Phase 1a and Phase 1b/2 trials, referred to as the ALPHA-STAR study, the drug has shown promising results in terms of both safety and efficacy. The data from these trials will be crucial in advancing the development of navenibart and potentially improving the lives of many HAE patients. In addition to navenibart, Astria Therapeutics is also advancing another promising drug, STAR-0310, an investigational monoclonal antibody OX40 antagonist for the treatment of atopic dermatitis. Atopic dermatitis is a chronic inflammatory skin condition that affects millions of people worldwide, causing symptoms like dry, itchy, and irritated skin. The development of STAR-0310 represents a significant step forward in finding novel treatments for this debilitating condition. Founded with a mission to revolutionize the treatment landscape for allergic and immunologic diseases, Astria Therapeutics is committed to bringing innovative solutions to patients and their families. The company's focus on monoclonal antibodies reflects its commitment to precision medicine, aiming to target specific biological pathways that underlie these conditions. For more information on Astria Therapeutics and its research programs, visit the company’s website at www.astriatx.com or follow them on social media platforms such as Instagram (@AstriaTx) and Facebook and LinkedIn. This announcement underscores Astria Therapeutics' active role in the scientific community and their dedication to advancing therapeutic options for patients suffering from complex and often overlooked conditions. The data presented at the workshop will be a pivotal contribution to the ongoing efforts to improve the management and treatment of HAE.